HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
Open Access
- 23 February 2012
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (6), 1160-1165
- https://doi.org/10.1038/bjc.2012.41
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Out-of-Pocket Costs for Accessing Adjuvant Radiotherapy Among Canadian Women With Breast CancerJournal of Clinical Oncology, 2011
- The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breastCancer, 2004
- Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.2003
- Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trialThe Lancet, 2003
- Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breastEuropean Journal of Cancer, 2003
- The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the BreastLaboratory Investigation, 2002
- Detection of Ductal Carcinoma In Situ in Women Undergoing Screening MammographyJNCI Journal of the National Cancer Institute, 2002
- Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853The Lancet, 2000
- Ductal carcinoma in situ: a proposal for a new classification.1994
- Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (Intraductal Carcinoma) of the breastInternational Journal of Radiation Oncology*Biology*Physics, 1994